Retrospective evaluation of two different thrombolytic agents in the treatment of patients with massive pulmonary embolism: Alteplase vs reteplase

Authors : Hakan Tanrıverdi, Ayşegül Tomruk Erdem, Bülent Altınsoy, Müge Meltem Tor

Pages : 313-319

Doi:10.29058/mjwbs.1551433

View : 59 | Download : 63

Publication Date : 2025-12-31

Article Type : Research Paper

Abstract :Aim: To compare clinical effectiveness of reteplase and alteplase in patients with massive pulmonary embolism. Material and Methods: Between 2010 and 2016 all patients treated with one of the thrombolytic agents, alteplase or reteplase, for massive pulmonary embolism were eligible for the study. We compared demographic data, hemodynamic parameters at baseline and at 2th, 4th, 6th, 12th, 24th hours after thrombolysis, the early and 1 year mortality rates and bleeding complications between two groups. Results: Seventy five patients (32 alteplase and 43 reteplase) were included study. Mean age was 64.2±13.6 years. Compared to the baseline values, hemodynamic parameters improved significantly at 2th, 4th, 6th, 12th and 24th hours after thrombolysis in both groups. In alteplase group, systolic blood pressure between baseline and at 6th and 12th hours altered significantly when compared with reteplase group. No significant difference was found in mortality rates and major bleeding events between groups. Minor bleeding events were higher in alteplase group than reteplase group, 28.1% vs 2.3%, respectively and the difference was significant. Conclusion: Reteplase seems as safe and effective as alteplase in the thrombolytic treatment of patients with massive pulmonary embolism.
Keywords : Alteplaz, doku plazminojen aktivatörü, pulmoner emboli, reteplaz trombolizis

ORIGINAL ARTICLE URL